Form D · Biotechnology

Akebia Therapeutics, Inc.

Cincinnati, OH · CIK 0001517022

Offering snapshot reported Apr 21, 2011 · SEC filing

Reported sold
$13.9M
Offering amount: $22.1M
Investors reported
24
Form D · investor count
Minimum accepted
$9K
Reported outside-investor minimum
First sale
Apr 6, 2011
As reported in this filing

Fundraising history

Reported sold
Reported amount sold by Form D filing date$0$6.97M$13.9MApr 8, 2011: $11,999,998.00Apr 8, 2011Apr 21, 2011: $13,945,340.00Apr 21, 2011

Dates are filing dates, not cash receipt dates. Decreases are reported revisions, not evidence of withdrawals. Separate offering histories are not added together.

What changed?

Latest filing versus its linked predecessor, where available.

  • Reported sold$11,999,998 → $13,945,340
  • Reported investors21 → 24

Filing history

Scroll to see all columns →

FiledFiling typeReported soldChange vs linked filingInvestorsSource
Apr 21, 2011Amendment$13,945,340$1,945,342vs Apr 8, 201124SEC filing
Apr 8, 2011Initial$11,999,998No comparison21SEC filing

Offering details

Securities
Equity
Exemptions
06
Duration over one year
No
Business combination
No
Sales commissions
$0
Finders' fees
$0
Form D file number
021-158098

Source: Form D, filed Apr 21, 2011. Minimum accepted may differ from a standard advertised minimum.

Fund connections

No confirmed ADV fund connection is available for this issuer.

People & organizations

Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.

People and organizations reported in Form D filings
NameReported role
Anupam Dalal Director
Joseph Gardner Director, Executive
Ian Howes Executive
Campbell Murray Director
Kevin Peters Executive
John Rice Director
Robert Shalwitz Executive
Paul Weiss Director

Issuer details

Industry: Biotechnology (See others in industry)

Address:
9987 Carver Road, Suite 420
Cincinnati, OH, 45242